(Nottingham, UK, 22 February 2008) – Molecular Profiles, a global leader in the provision of innovative contract research services to the pharmaceutical, biopharmaceutical and biomedical sectors worldwide, announces two new significant additions to the team. Dr. Mike Fanfarillo has joined Molecular Profiles as Operations Director and Dr. Robert Sherry as Associate Director in Pharmaceutics.
As Operations Director, Mike Fanfarillo is responsible for the management of research projects and the development of the technical team,and services at Molecular Profiles. Mike is also a Study Director on numerous patent related projects. Mike’s expertise covers the range of preparative, analytical and characterisation techniques used in the pharmaceutical development of medicinal products, from chromatography to spectroscopy. Mike also has extensive experience of writing and assembling Drug Product Licence applications, writing Pharmaceutical Expert Reports and assessment of API Drug Master Files from third party manufacturers.
Mike graduated in chemistry from the University of Manchester and then completed a D.Phil in chemistry at the University of Oxford. He has over 20 years’ experience in the pharmaceutical industry having worked for ICI/Zeneca Pharmaceuticals, Boots Healthcare International and Reckitt Benckiser Healthcare International.
In his role as Associate Director in Pharmaceutics, Bob Sherry is an expert in a wide range of product dose forms, consulting on a range of formulation issues facing pharmaceutical companies in the development of their products, including utilizing outputs from investigations to assert intellectual property rights for these clients. Bob is also responsible for directing technical studies to resolve complex formulation issues and for developing collaborations with academic and industrial experts. Bob has particular experience of regulatory requirements for new licence submissions, clinical trials manufacture and significant patent experience, with several formulation and process patents granted.
Bob received his PhD in physical chemistry from Leicester University, where he used a number of spectroscopic and analytical techniques to study reaction kinetics. He has over 20 years of industrial experience at Boots Healthcare International covering a wide range of formulation types and product formats.
“We are delighted to announce these two new appointments as an expansion to our team”, comments Dr. Nikin Patel, CEO, Molecular Profiles. “Following on from the recent successful recruitment of a number of experienced scientists, both Mike’s and Robert’s extensive specialisms reinforce Molecular Profile’s commitment to enhancing our in-house expertise and service offering.”
Molecular Profiles’ services can be broadly categorised into three key areas: formulation support (including pre-formulation and product R&D); rapid problem solving (during pre-formulation right through to manufacturing); and patent and litigation support. Molecular Profiles have a range of expert witnesses who lead multidisciplinary teams that can attest to international experience of deposition and trial testimony in support of litigation issues.
More information about Molecular Profiles’ award-winning services is available at www.molprofiles.co.uk, by e-mail at firstname.lastname@example.org, alternatively, call Dr. Nikin Patel on +44 115 8718888.
About Molecular Profiles
Molecular Profiles is a leader in the provision of innovative contract research services to the pharmaceutical, biopharmaceutical and biomedical sectors worldwide. The company is a recipient of a Queen’s Award for Enterprise in the Continuous Innovation and Development category. The award saw the company and its complete range of services recognised as one of the UK’s most innovative during 2007. The services include nanoscreening technology for predicting the ease of development of a new medicine, a deformulation service for identifying problems with a product down to the nanoscale, and advanced imaging for viewing and optimising the internal structure of products.